Clinical Trial Update: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole [Phase 3]

View source ↗

Summary

Phase 3, randomized, double-blind trial evaluating ibrexafungerp vs fluconazole after IV echinocandin for invasive candidiasis and candidemia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Candidemia
• Invasive Candidiasis

Drugs mentioned

• Fluconazole (Fluconazole)
• Ibrexafungerp (ibrexafungerp)

Snippet

Sponsor: Scynexis, Inc. | Conditions: Candidiasis, Invasive, Candidemia | Phase 3 | Status: TERMINATED